• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 461654 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419046498 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419046498 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulate Shares of United Therapeutics, Up 1.6%

Published on Mon, 03/18/2013 - 12:29
By Mallory Stone

United Therapeutics (NASDAQ:UTHR), a company whose shares are moving quickly, is trading 1.6% higher to $62.01. The Dow is trading fractionally lower to 14,492 and the S&P is currently down 0.3% to 1,555.

In the past 52 weeks, United Therapeutics share prices have been bracketed by a low of $36.55 and a high of $70.74 and are now at $62.01, 70% above that low price. The 200-day and 50-day moving averages have moved 0.90% higher and 1.65% higher over the past week, respectively.

United Therapeutics (NASDAQ:UTHR) is currently priced 8.5% above its average consensus analyst price target of $56.73. The stock should discover initial support at its 50-day moving average (MA) of $55.84 and subsequent support at its 200-day MA of $53.10.

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Shares of Wells Fargo Rise to a New 52-W...

Wells Fargo (NYSE:WFC) traded at a new 52-week high today of $55.42. Approximately 20. ...

Watch for Continued Gains in Shares of W...

Wisconsin Energy (NYSE:WEC) traded today at a new 52-week high of $52.50. So far today ...

Recent 52-Week High Exceeded in Shares o...

Shares of Western Digital (NYSE:WDC) traded today at $114.69, breaking its 52-week high ...

WellCare Health Plans: The Winning Strea...

Shares of WellCare Health Plans (NYSE:WCG) traded at a new 52-week high today of $80.95 ...

Vertex Pharmaceuticals Looks to Continue...

Vertex Pharmaceuticals (NASDAQ:VRTX) traded at a new 52-week high today of $123.82. Th ...

Shares of Vornado Realty Trust Rise Abov...

Shares of Vornado Realty Trust (NYSE:VNO) traded today at $117.37, breaking its 52-week ...

US Bancorp Looks to Continue to Trade Ab...

Shares of US Bancorp (NYSE:USB) traded today at $45.54, breaking its 52-week high. So ...

United Parcel Service Looks to Continue ...

United Parcel Service (NYSE:UPS) traded today at a new 52-week high of $111.99. So far ...